Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest XENTION LTD Stories

2012-03-19 22:20:56

CAMBRIDGE, England, March 20, 2012 /PRNewswire/ -- XEN-D0103, a potent and selective Kv1.5 antagonist, is safe and well tolerated in healthy volunteers XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally. The drug, a selective inhibitor of the cardiac potassium channel Kv1.5, was well tolerated and...